MB 105
Alternative Names: MB-105 - March Biosciences; MB105Latest Information Update: 16 Aug 2024
At a glance
- Originator March Biosciences
- Developer Baylor College of Medicine; March Biosciences
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Precursor T-cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Preclinical Chronic lymphocytic leukaemia; Mantle-cell lymphoma
Most Recent Events
- 02 Aug 2024 March Biosciences plans a phase II trial for T-cell Lymphoma (Second-line therapy or greater) in February 2025 (NCT06534060)
- 09 Nov 2023 Phase-I clinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in USA (Parenteral) (NCT03081910)
- 09 Nov 2023 Phase-I clinical trials in T-cell lymphoma (Second-line therapy or greater) in USA (Parenteral) (NCT03081910)